Barclays raised the firm’s price target on Abbott (ABT) to $169 from $162 and keeps an Overweight rating on the shares. The firm upped sales and earnings estimates for Abbott in 2027 and beyond.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- 3 Best Dividend Aristocrat Stocks to Buy in 2026
- Unusually active option classes on open December 30th
- Abbott Laboratories: Buy Rating Backed by Volt PFA-Driven Incremental Growth and Strengthening Electrophysiology Position
- Abbott announces FDA approval of Volt PFA System to treat AFib
- Abbott’s Amplatzer Piccolo Delivery System granted FDA and CE clearance